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Abstract
Background: The purpose of this study was to compare the efficacy of electroacupuncture (EA),
diclofenac and their combination in symptomatic treatment of osteoarthritis (OA) of the knee.
Methods: This study was a randomized, single-blind, placebo controlled trial. The 193 out-patients
with OA of the knee were randomized into four groups: placebo, diclofenac, EA and combined
(diclofenac plus EA). Paracetamol tablets were prescribed as a rescue analgesic during the study.
The patients were evaluated after a run-in period of one week (week 0) and again at the end of the
study (week 4). The clinical assessments included the amount of paracetamol taken/week, visual
analog scale (VAS), Western Ontario and McMaster Universities (WOMAC) OA Index, Lequesne's
functional index, 50 feet-walk time, and the orthopedist's and patient's opinion of change.
Results: One hundred and eighty six patients completed the study. The improvement of symptoms
(reduction in mean changes) in most outcome parameters was greatest in the EA group. The
proportions of responders and patients with an overall opinion of "much better" were also greatest
in the EA group. The improvement in VAS was significantly different between the EA and placebo
group as well as the EA and diclofenac group. The improvement in Lequesne's functional index also
differed significantly between the EA and placebo group. In addition, there was a significant
improvement in WOMAC pain index between the combined and placebo group.
Conclusion: EA is significantly more effective than placebo and diclofenac in the symptomatic
treatment of OA of the knee in some circumstances. However, the combination of EA and
diclofenac treatment was no more effective than EA treatment alone.
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Background
Osteoarthritis (OA) is the most common joint disease. Ar-
ticular cartilage in OA has shown to lose its mechanical re-
sistance, elasticity and smoothness, and is consequently
worn out by the movements of the joint. This leads to re-
active bone remodeling, forming osteophytes, microfrac-
tures, subchondral eburnation and pseudocysts, and
exposure of the articular end of the bone [1]. The conse-
quent roughness of the articular cartilage surfaces elicits
secondary inflammatory reactions of the synovial mem-
brane and bone. Unlike rheumatoid arthritis and other in-
flammatory joint diseases, the inflammatory component
of OA is relatively mild [2,3]. Clinical manifestations of
OA of the knee are joint pain, stiffness in the morning or
after rest, pain at night, limited joint motion and/or joint
deformity. Joint pain in OA may originate from not only
synovitis, but also stretching of the joint capsule or liga-
ments, periosteal irritation due to osteophyte formation,
trabecular microfractures, intraosseous hypertension, or
muscle spasm [4–7].
There are many treatment modalities for OA of the knee
including nonpharmacologic (e.g. patient education,
weight control, physical and occupational therapy, and
aerobic exercise programs) and pharmacologic therapy
(e.g. intraarticular steroid injections, paracetamol, topical
analgesics, nonsteroidal anti-inflammatory drugs
(NSAIDs) and opioid analgesics) [8]. Although NSAIDs
are the most widely prescribed drugs to reduce joint pain
and stiffness, the inflammatory component of OA is usu-
ally minimal, therefore, the need for the anti-inflammato-
ry effect of NSAIDs in this condition is controversial
[2,9,10]. Moreover, inhibition of prostaglandin biosyn-
thesis is directly related to many common and occasional-
ly severe side effects including gastrointestinal bleeding,
hypertension, congestive heart failure, hyperkalemia, and
renal insufficiency [11–14]. These disadvantages call for
an evaluation of the risks and benefits of the therapy in
comparison with a less toxic one for OA.
Since the efficacy of NSAIDs in symptomatic treatment of
OA of the knee depends on the analgesic rather than anti-
inflammatory effect, paracetamol (analgesic drug) has
been recently recommended as the first-line oral drug in
the management of OA of the knee [8]. However, the long
term use of paracetamol probably leads to hepatic and re-
nal impairment [15,16]. Thus, less toxic pain managing
procedures, e.g. electroacupuncture (EA), may be consid-
ered as an alternative treatment of this disease. Even
though EA is safe and effective in combating pain [17,18],
its role in OA of the knee is still controversial and compar-
ative studies between EA and NSAIDs in this disease are
rare [19]. Therefore, the aim of this study was to compare
the efficacy of EA, diclofenac and their combination in
short-term, symptomatic treatment of OA of the knee.
Materials and methods
Research design
This study was a randomized, single-blind, placebo con-
trolled trial. The treatment procedures consisted of place-
bo tablet plus placebo EA (placebo group), diclofenac
tablet plus placebo EA (diclofenac group), placebo tablet
plus true EA (EA group) and diclofenac tablet plus true EA
(combined group). This study was approved by the Medi-
cal Ethics Committee of the Faculty of Medicine, Chiang
Mai University and was in compliance with the Helsinki
Declaration.
Subjects
Two hundred out-patients of either sex, aged over 40
years, and who had been suffering from unilateral or bi-
lateral OA of the knee according to the criteria of the
American College of Rheumatology [8] for more than 3
months duration, were recruited. Lequesne's functional
index, which was evaluated at the screening visit, had to
be at least 6 points. Subjects had to be able to walk and
give both verbal and written information regarding the
study. Signed informed consent was obtained prior to en-
try. Exclusion criteria included an underlying inflammato-
ry arthropathy, expectation of surgery in the future, recent
injury in the area affected by OA of the knee, intraarticular
corticosteroid injections or EA within the last 3 months,
hypersensitivity to NSAIDs or paracetamol, abnormal liv-
er or kidney function tests, evidence of leukopenia and co-
agulopathies screened by clinical laboratory,
concomitantly receiving anticoagulants, history of peptic
ulceration, anemia, uncontrolled hypertension, conges-




During a run-in period of one week, the patients refrained
from using any NSAIDs or analgesics except for a "rescue
analgesic" (2 tablets of 500 mg paracetamol orally as
needed, up to 4 times daily). The patients who had persist-
ent pain and a Lequesne's functional index of at least 6
points at the end of the run-in period were randomized
into the four groups mentioned above. Diclofenac sodi-
um, 25 mg film-coated tablets were a gift from Novartis
(Thailand) Limited. Placebo and diclofenac were pre-
pared in identical appearance. Either the placebo or di-
clofenac was prescribed at 1 tablet, 3 times a day
immediately after each meal for 4 weeks. In addition, 2
tablets of 500 mg paracetamol were still prescribed as a
"rescue analgesic" during this study.
2. True and placebo EA
The true EA treatment was standardized throughout the
study. It was performed by the physician acupuncturist
who received acupuncture training in the People's Repub-BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/3
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lic of China. Four fine stainless steel needles were inserted
into acupuncture points around the affected knee [20] as
presented in Table 1 and Figure 1. All needles were used
in order to conduct an electrical current through the
points, and were inserted superficially (not more than 0.5
inch approximately in depth). Thus, an elicitation of nee-
dle sensation (so-called De Qi) during the insertion of the
needles was not intended. The first pair of electrodes was
connected to the Dubi and nearest adjacent point (medial
Xiyan) and the second pair to the trigger point and Qu-
quan. The electrical stimulation was applied slowly and
simultaneously to each pair of needles until it reached the
maximum toleration level of the patient. Biphasic pulses
were used for the electrical stimulation at a frequency of 2
Hz, and it was administered for 20 minutes in each treat-
ment. The patients were treated 3 times a week (Monday,
Wednesday, and Friday) for 4 weeks (12 times).
The placebo EA was performed by attaching patch elec-
trodes to the selected acupuncture points. Each electrode
was connected to the sound producing dummy mode of
the same apparatus, as in the true EA treatment. The dura-
tion and frequency of treatment were the same as those in
the true EA treatment. Both true and placebo EA were per-
formed by the same physician. Thus, the physician acu-
puncturist was the only person in the research team who
knew which patients received the true or placebo EA.
Compliance with treatment was assessed by counting the
number of unused tablets (diclofenac or placebo) and the
number of times acupuncture treatment was received.
During the study period, all additional therapies (e.g. oral
or topical NSAIDs, intraarticular corticosteroid injection,
other analgesics, chondro-protective agents, surgical pro-
cedures on the knee joint etc.) were not allowed. Howev-
er, all other treatment for concomitant disorders that did
not interfere with the study could be continued, but it had
to be documented.
Assessments
Clinical assessments were evaluated for base-line data at
the end of the run-in period (week 0) and again at the end
of the study (week 4). These assessments included the
amount of paracetamol tablets taken/week, 50 feet-walk
time, a patient's global pain as 100 mm visual analog scale
(VAS) over the previous 3 days, the Western Ontario and
McMaster Universities OA Index (WOMAC: score ranging
from 0–96) [21], and Lequesne's functional index (score
ranging from 0–24) [22]. At the end of this study, the or-
thopedist's and patient's opinion of change (much better,
better, same, worse, much worse) were evaluated. The pa-
tients were considered to be responders if they met the fol-
lowing criteria. Firstly, the number of paracetamol tablets
taken in week 4 was less than that at week 0, or less than
14 tablets/week. Secondly, at least 4 of the following 5
outcome parameters showed the following improvement:
VAS, WOMAC, Lequesne's functional index decreased by
at least 50%, and the orthopedist's or patient's overall
opinion of change was better or much better. Clinical as-
sessments in each patient were evaluated by the same phy-
sician who was blinded to the treatment. Complete
physical examination and non-directive questioning for
adverse events were also performed weekly for 4 weeks in
order to acquire a safety assessment.
Statistical analysis
One-way analysis of variance (ANOVA) was used to deter-
mine whether the four treatment groups differed in mean
values of change from a base-line in paracetamol con-
sumption, 50 feet-walk time, VAS, WOMAC and
Lequesne's functional index. If there was any statistical
significance between any of the four groups, the Scheffe
method was used to demonstrate statistical significance
between each of two groups. Differences among the treat-
ment groups in the overall opinion of change, and
number of patients considered to be responders, were
evaluated by chi-square or Fisher's exact test.
Results
Of the 200 subjects considered eligible for the study, 5
dropped out and 2 were withdrawn during the run-in pe-
riod due to hypersensitivity to paracetamol and spontane-
ous pain relief. The remaining 193 subjects constituted
the study population and were randomized into four par-
allel groups, which were not significantly different in
base-line characteristics (Table 2) and radiographic find-
Figure 1
The selected acupuncture points around the knee, demon-
strated in sitting position, during treatment with true (A) and
placebo EA (B).BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/3
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ings of affected knees (Table 3). Only 1 patient in each
placebo, EA and combined group as well as 2 patients in
the diclofenac group received acupuncture treatment prior
to this study.
Of the 193 study patients, 186 (96.37%) completed the
study. The remaining 7 patients were withdrawn from the
trial due to flare of pain with joint swelling (2 in the pla-
cebo and 1 in the EA group), severe GI side effects (3 in the
combined group), and flare of pain from an accidental fall
not related to treatment (1 in the EA group). Since there
were few patients withdrawn from the trial, the results
were, therefore, not substantially affected, whether the
analysis was performed by an intention to treat analysis or
an analysis on available completers. Thus, the following
data showed the findings in only 186 available compl-
eters.
During 4 weeks of treatment, change in body weight com-
pared to the base-line values did not significantly differ
among the four groups (one-way ANOVA calculated
weekly, data not shown). The rates of compliance with
medications (placebo or diclofenac) and acupuncture
(placebo or EA) in each group were more than 90%, and
comparable among the four groups.
Table 1: The selected acupuncture points used in this study.
Acupuncture points Location Needling manipulation
Dubi (ST-35)1 In the depression of the lateral part of the patella ligament, when the knee is bent. Slightly towards the medial side*.
Medial Xiyan (Extra)1 In the depression of the medial part of the patella ligament, when the knee is bent. Slightly towards the lateral side**.
Trigger point2 At the level of the joint line, midpoint between the medial Xiyan and Ququan. Straight insertion*.
Ququan (Liv-8)2 At the medial end of the knee crease, in front of the semi-membranous muscle 
behind the lower end of the femur.
Straight insertion**.
1First pair of elctrodes 2Second pair of electrodes *Stimulated with positive polarity at visit #1, 3, 5, 7,9,11 and negative polarity at visit #2, 4, 6, 8, 
10, 12. **Stimulated with negative polarity at visit #1, 3, 5, 7,9,11 and positive polarity at visit #2, 4, 6, 8, 10, 12.
Table 2: Base-line characteristics of patients evaluated at the end of the run-in period.
Treatment groups
Characteristic Placebo Diclofenac EA Combined p-value **
n (M:F) 47 (12:35) 49 (11:38) 48 (10:38) 49 (10:39) 0.93c
Age (yr)* 62.70 (7.22) 62.14 (7.53) 65.10 (3.40) 61.84 (8.95) 0.16a
Body weight (kg)* 60.65 (10.24) 57.65 (10.64) 59.89 (9.74) 59.92 (9.66) 0.49a
Height (cm)* 153.94 (6.45) 151.94 (10.71) 152.19 (5.89) 153.32 (6.73) 0.54a
Duration of OA (yr)* 4.98 (3.32) 3.94 (2.83) 6.09 (4.96) 4.53 (3.86) 0.05a
Localization of OA 0.40c
Right/Left knee 2/3 2/6 1/4 3/5
Both knees 42 41 43 41
Number of paracetamol tablets taken per week* 22.06 (13.75) 18.94 (14.68) 21.40 (14.97) 19.04 (14.87) 0.63a
50 ft-walk time (sec)* 22.04 (4.81) 22.36 (6.00) 24.54 (8.14) 22.77 (5.13) 0.21a
VAS* 63.49 (22.36) 64.79 (23.41) 66.87 (22.34) 57.63 (21.21) 0.21a
WOMAC*
Pain index 10.19 (4.20) 11.02 (4.15) 10.25 (3.86) 10.50 (4.18) 0.75a
Stiffness index 4.51 (1.71) 4.08 (1.95) 4.35 (2.10) 4.27 (1.57) 0.72a
Disability index 37.04 (12.00) 35.65 (12.89) 38.00 (13.18) 37.94 (13.02) 0.79a
Total score 51.75 (15.96) 50.76 (17.98) 52.60 (18.13) 52.71 (17.65) 0.94a
Lequesne's functional index* 13.78 (3.78) 13.85 (3.22) 14.14 (2.98) 13.73 (2.92) 0.93a
*Data represent mean (SD) **Statistic analysis: a = one-way ANOVA, c = chi-square test.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/3
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At the end of the study, the improvement of symptoms,
which were determined by the reduction in mean changes
in most outcome parameters (except WOMAC pain index
and WOMAC total score), was greatest in the EA group
(Table 4). The mean changes in VAS were significantly dif-
ferent between the EA and placebo group as well as the EA
and diclofenac group (Table 4 and Figure 2). The mean
changes in the Lequesne's functional index also differed
significantly between the EA and placebo group (Table 4,
Figure 3). In addition, there were significant differences in
mean changes in the subscale of standardized WOMAC
(pain index) between the combined and placebo group
(Table 4 and Figure 4). The proportion of patients with
the orthopedist's and patient's overall opinion of "much
better" was greatest in the EA group, followed by the di-
clofenac, combined and placebo group, respectively. In
addition, the proportion of responders was also greatest
in the EA group, followed by the combined, diclofenac
Table 3: The radiographic findings at entry into the study*.
Treatment groups
Radiographic findings Placebo (89 knees) Diclofen ac (90 knees) EA (91 knees) Combined 
(90 knees)
p-value
Kellgren and Lawrence X-ray grade [32]
Grade 1 4 1 3 5 0.40f
Grade 2 4 6 5 7 0.84f
Grade 3 19 15 25 23 0.31c
Grade 4 62 68 58 55 0.16c
Knee compartment with most severe change of OA
Medial tibiofemoral 63 77 69 64 0.73c
Lateral tibiofemoral 12 5 13 11 0.24c
Patellofemoral 14 8 9 15 0.28c
Data represent number of patients. Statistic analysis: c = chi-square test, f = Fisher's exact test.
Figure 2
Change in 100 mm VAS in each treatment group evaluated at
the end of week 4. Values are mean ± SEM. * = p < 0.05



































Change in Lequesne's functional index in each treatment
group evaluated at the end of week 4. Values are mean ±
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and placebo group, respectively. However, statistical dif-
ferences among the four groups were found only in the or-
thopedist's overall opinion and a number of responders
(Table 5). There were no differences between the four
groups in the remaining outcome parameters.
The percentage of patients who experienced adverse ef-
fects (e.g. gastrointestinal and central nervous system
symptoms, rash, edema, and hypertension) during this
study did not differ between the four groups (data not
shown), whereas, local contusions around the knee were
common in the EA and combined group (approximately
45%). However, the contusions usually disappeared with-
in 5–7 days.
When the responders in each group were followed up for
2 months, the proportion of remaining responders was
not significantly different between the four groups (Table
6).
Discussion
Although there are several lines of evidence from many
controlled and uncontrolled studies for the short-term
and long-term effectiveness of acupuncture in relieving
clinical pain [23–28], the scientific data concerning the ef-
ficacy of acupuncture in OA are rare [19]. In addition,
there are several systemic flaws [29] among these studies
due to inadequate statistical power, inadequate sessions
of acupuncture treatment, failure to control concomitant
therapies, or no sham/placebo acupuncture controlled
group. In this study, we minimized the methodological
limitations of previous studies by using the randomized,
single-blind, placebo controlled design with a larger sam-
ple size of OA patients coupled with standard outcome as-
sessments. By using the percentage of the responders as
the main efficacy criterion, the comparison between true
and sham acupuncture needs at least 61 patients per
group, whereas, only 35 patients per group are needed to
compare between true and placebo acupuncture per-
formed by not puncturing the skin [23,30]. In order to in-
crease the ability of differentiating true from placebo
effects and minimize the sample size, we selected the pro-
cedure of attaching the acupuncture points with the patch
electrodes as placebo EA, and at least 45 completers per
group were treated in this trial. In this study, a double-
blind design was considered inappropriate, since we used
patch electrodes as placebo EA and our patients might
have recognized the difference between true and placebo
EA. A single blind was, therefore, a reasonable alternative.
The acupuncture points used were selected because we in-
tended to determine only the effects of local points
around the affected knee. This applied especially to the
medial aspect, which related to the knee compartment
that was frequently involved in OA. Using these local
points coupled with the needling technique (developed
by Chawal Kanchanakul, acupuncturist of Dhammana-
mai Foundation, Chiang Mai, Thailand) demonstrated a
rather simple, convenient, less painful, and more accepta-
ble method for Thai patients, and it was effective in our pi-
lot study. The points selected here were therefore different
from other trials [24–26,28], which also included the dis-
tal points at medial and lateral aspects of the leg. Low-fre-
quency (2 Hz) EA was selected because it produces an
analgesia of long duration, which outlasts the 20-min
stimulation session by 30 min to many hours. In addi-
tion, its effects are cumulative after several sessions of
treatment given either daily or less frequently (2–3 times
a week) [30]. For these reasons, the low-frequency EA in
this study was therefore given 3 times a week for 4 weeks,
as commonly recommended in EA practice. However, to
balance the acupuncture point stimulation by positive
and negative polarities, each point was stimulated 6 times
with positive and negative polarities in an alternate se-
quence during 12 sessions of treatment. In addition, each
pair of electrodes was connected to each pair of adjacent
points in order to obtain equal electrical sensation in each
point during stimulation.
In this study, the clinical responses observed in the place-
bo group might result from, 1) the placebo effect or natu-
ral fluctuations in the symptoms of OA that are unrelated
to the analgesic effect of paracetamol, because some pa-
tients demonstrated reductions in these scores without or
Figure 4
Change in WOMAC pain index in each treatment group
evaluated at the end of week 4. Values are mean ± SEM. * = p
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with minimal analgesic need, or 2) the direct effects of pa-
racetamol as a rescue analgesic. The latter reason made the
placebo group not absolutely inert because paracetamol is
also the first-line drug in the treatment of OA of the knee.
However, the use of a rescue analgesic could not be avoid-
ed due to ethical reasons.
At week 4, the improvement of symptom scores (except
change in WOMAC pain index and WOMAC total score)
and the number of responders/patients with the opinion
of "much better" were greatest in the EA group. These data
indicate the great potential of EA in the symptomatic
treatment of OA of the knee. This study also demonstrated
that EA was significantly more effective than placebo with
respect to changes in VAS and Lequesne's functional in-
dex, and significantly more effective than diclofenac with
respect to the changes in VAS. This superiority of EA indi-
cates its genuine efficacy [17,23,30], which was more ef-
fective than placebo (or diclofenac) in this study. A
previous trial revealed 34% and 14% reductions in the
Table 4: Change in outcome parameters after 4 weeks of treatment*.
Treatment groups
Parameter Placebo (n = 45) Diclofenac (n = 49) EA (n = 46) Combined (n = 46) p-valuea
Number of paracetamol taken (tablets 
taken per week)
-5.16 (2.33) -4.43 (1.90) -7.89 (2.09) -5.13 (2.06) NS
50 feet-walk time (sec) -2.70 (0.52) -3.52 (0.46) -4.41 (0.70) -4.13 (0.54) NS
VAS -22.86 (4.02) -32.99 (3.94) -48.24 (3.59) -35.59 (2.74) <0.05†
WOMAC
Pain index -3.31 (0.68) -4.90 (0.53) -5.65 (0.59) -6.28 (0.77) <0.05††
Stiffness index -1.47 (0.31) -1.55 (0.27) -2.24 (0.31) -2.02 (0.28) NS
Disability index -12.33 (1.88) -14.39 (1.77) -19.17 (2.05) -18.98 (1.92) NS
Total score -17.11 (2.73) -20.84 (2.43) -27.07 (2.78) -27.28 (2.79) NS
Lequesne's functional index -3.82 (0.51) -4.80 (0.61) -6.44 (0.59) -5.39 (0.52) <0.05†††
*Compared values of week 4 versus those of week 0 (run-in peroid), data represent mean (SEM). Statistic analysis: a = one-way ANOVA and 
Scheffe method. NS= no statistical significance. † = EA vs placebo and diclofenac group. †† = combined vs placebo group. ††† = EA vs placebo group.
Table 5: Overall opinions of change and number of responders evaluated at week 4.
Treatment groups
Parameter Placebo (n = 45) Diclofenac (n = 49) EA (n = 46) Combined (n = 46) p-value
Orthopedist's overall opinion* 0.01†
Much better 6 18 21 16
Better 22 21 20 23
Same 16 10 5 7
Worse 1 0 0 0
Patient's overall opinion* 0.09†
Much better 19 25 31 22
Better 16 17 11 23
Same 9 7 4 1
Worse 1 0 0 0
Number of responders 13 18 27 24 0.02††
*Data represent number of patients, † = chi-square test evaluated on the proportions of patients with the opinion of "much better", †† = chi-square 
test.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/3
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mean values of WOMAC total score and Lequesne's index,
respectively after 4 weeks of acupuncture treatment [28],
whereas, our study demonstrated a 50% and 45% reduc-
tion, respectively. These discrepancies might be due to dif-
ferences in acupuncture point selection, number of points
and the electrical stimulation technique used, or electrical
stimulation parameters.
The clinical responses in the combined group were slight-
ly superior to the diclofenac group, but not to the EA
group (except for the tendency of being superior with re-
spect to a change in the subscale of the standardized
WOMAC: pain index). These responses indicate that EA
may exert an adequate analgesic effect, a combination
with diclofenac may not be of further benefit. Although a
combination was not more efficacious than EA alone, it
was significantly more so compared to placebo in terms of
improvement in the WOMAC pain index, while EA was
not. However, the nonsignificant change in clinical scores
between the diclofenac and placebo group indirectly sug-
gests that diclofenac may be as effective as paracetamol (as
needed) in symptomatic treatment of OA of the knee.
The nonsignificant change in paracetamol consumption
among the four groups during treatment might result
from the unnecessary use of paracetamol in a great major-
ity of active treatment groups, despite a significant im-
provement in some parameters of the EA and combined
group, and a tendency to improve parameters in the di-
clofenac group. Another possibility might be the large var-
iation in paracetamol consumption in each group that
contributed to a false negative result. The nonsignificant
change in the 50 feet-walk time among the four groups
suggests that this parameter may not be sensitive enough
to demonstrate existing differences. Walk time deter-
mined during stair climbing should thus be a better alter-
native [31]. The failure to demonstrate the differences in
other parameters (i.e. change in WOMAC stiffness, disa-
bility, and total scores) between the active treatment and
placebo group may be due mainly to the rescue analgesic
and partly to inadequacy of the sample size.
This study demonstrated that EA treatment was safe and
free from serious adverse effects. However, the indiffer-
ence in adverse events between the diclofenac and place-
bo group might be due to the exclusion of patients who
were at high risk to the adverse effects of NSAIDs during
the screening visit or short-term trial. In this study, the res-
cue analgesic paracetamol contributed to several con-
founding effects. Therefore, the randomized placebo
controlled trial without using rescue analgesic should be
investigated further to confirm the effectiveness of this
range of active treatment, especially in EA and its combi-
nation with NSAIDs.
In summary, EA was significantly more effective than pla-
cebo regarding reductions in 100 mm VAS and Lequesne's
functional index, but was significantly more effective than
diclofenac in only the reduction of 100 mm VAS. The
combination of EA and diclofenac treatment was more ef-
fective than placebo with respect to the reduction in the
subscale of standardized WOMAC (pain index), but not
more effective than EA treatment alone. Local contusions
were minor adverse effects commonly found in the EA
and combined group. The positive effects far outweigh the
serious adverse ones of EA, which make this procedure an




Table 6: Number of responders considered at the end of the study (week 4) and at 1 and 2 month(s) after treatment*.
1 month after treatment 2 months after treatment
Treatment groups responders at week 4 remaining responders/ evaluated responders† remaining responders/ evaluated responders†
Placebo 13 11/12 9/12
Diclofenac 18 10/16 7/15
EA 27 21/25 19/24
Combined 24 14/24 14/24
p value** 0.12 0.19
* Only the responders at the end of the study were followed up for 2 months. †Some patients were unable to be evaluated due to loss of follow up 
or use of NSAIDs for other purposes during the follow-up period. ** Fisher test between the four groups.BMC Complementary and Alternative Medicine 2002, 2 http://www.biomedcentral.com/1472-6882/2/3
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